Oncolytics Biotech Inc. (ONCY)

[justthefactsmam]

oncolytics currently doing a run-in study for muscle invasive bladder cancer. this would come under the "soft tissue sarcoma" referenced in prior post. currently this is only a clinical trial which it is hoped will progress to a registration study sometime early in 2016. again, interesting that care plus considers the use of reolysin as reimbursable in 2016, again without any marketing approvals currently received.

wonder, since this us a clinical trial study, that care plus is looking at this as an off-label reimbursable item?

if one is in a clinical trial, the cost of the drugs are paid for by the sponsers or just supplied "for free" by the pharma whose drug is being tested. in any case, doesn't seem that it would be something to be reimbursed by an insurance company at this point.

wonder if this points to an early 2016 approval for some indication currently under study by oncolytics?